HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PF 956980

structure in first source

Also Known As:

PF-956980; PF956980

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - PF 956980: 3
  - Pyrimidines: 510
    - PF 956980: 3

Experts

1.	Barnes, Peter J: 1 article (01/2015)
2.	Donnelly, Louise E: 1 article (01/2015)
3.	Fenwick, Peter S: 1 article (01/2015)
4.	Kilty, Iain C: 1 article (01/2015)
5.	Macedo, Patricia: 1 article (01/2015)
6.	Cwynarski, Kate: 1 article (11/2010)
7.	Hart, Stephen M: 1 article (11/2010)
8.	Hoffbrand, A Victor: 1 article (11/2010)
9.	Lowdell, Mark W: 1 article (11/2010)
10.	Prentice, Archibald G: 1 article (11/2010)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2015 - "These data suggest that the novel JAK inhibitor, PF1367550, is more potent than PF956980 and that JAK pathway inhibition in airway epithelium could provide an alternative anti-inflammatory approach for glucocorticosteroid-resistant diseases including COPD." 01/01/2015 - "This study compared the efficacy of two structurally dissimilar pan-JAK inhibitors, PF956980 and PF1367550, and the glucocorticosteroid dexamethasone, in BEAS-2B and human primary airway epithelial cells from COPD patients and control subjects. "
2.	Rheumatoid Arthritis 02/15/2008 - "PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compound being evaluated in clinical trials for rheumatoid arthritis and prevention of allograft rejection. "
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/25/2010 - "The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment."

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Janus Kinase Inhibitors
3.	tofacitinib
4.	Interleukin-4 (Interleukin 4)
5.	Cytotoxins (Cytolysins)